Three inVentiv Health Leaders Recognized in 2011 PharmaVOICE 100

BURLINGTON, Mass., Aug. 1, 2011 /PRNewswire/ -- inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced that leaders from three inVentiv Health companies were named to PharmaVOICE's 2011 list of the "100 Most Inspiring People" in healthcare. inVentiv honorees were Joe Daley of GSW Worldwide, Gregg Dearhammer of i3 and Uwe Tigor of Palio.

• Joe Daley is President of North American Operations for GSW Worldwide, one of the world's largest global healthcare advertising agencies. Based in Columbus, Ohio, Daley has been instrumental in strengthening the agency's core capabilities and growing GSW's business in the U.S., Canada and Mexico. Daley was nominated in part for being an advocate for fostering an entrepreneurial spirit and for energizing and inspiring his team to believe that if they search for a new idea or way of doing something, it can be implemented and it can make a difference.
• Gregg Dearhammer is President of FSP/Staffing services for i3, part of the inVentiv Health Clinical segment, and is based in Ann Arbor, Mich. An accomplished leader, Dearhammer has more than 10 years experience in senior management positions at clinical research organizations in the field of data services. He is an active member of the Society for Clinical Data Management (SCDM) and has chaired, developed and spoken at various conference sessions. Dearhammer currently serves on the SCDM Board of Trustees.
• Uwe Tigor, M.D., is the Chief Medical Officer of Palio, an advertising agency revolutionizing pharmaceutical and healthcare marketing. Based in Saratoga Springs, N.Y., Tigor oversees the agency's medical strategy and editorial departments and is the force behind the agency's REMS programs and regulatory compliance. Tigor has extensive experience across a range of therapeutic areas, including cardiovascular disease, diabetes, sepsis, psoriasis, Alzheimer's disease, glaucoma, psychiatry/neurology, pulmonary disease, oncology, stroke, osteoporosis and gastroenterology.

Each year in its July/August issue, PharmaVOICE magazine recognizes 100 individuals in the healthcare industry who inspire and motivate those around them, who mentor and lead and who contribute significantly to their organization.

About inVentiv Health

inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses, including the acquisitions of i3 and PharmaNet Development Group, Inc., into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance; and changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing. Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.

SOURCE inVentiv Health